Sotera Health Company

Mission-critical sterilization and lab testing for medical devices, pharmaceuticals, and food. Three units: Sterigenics (terminal sterilization — gamma, EO, e-beam), Nordion (gamma technologies/Cobalt-60 supply), Nelson Labs (microbiological/analytical testing). Once a device manufacturer validates a sterilization process with Sotera, switching is expensive and risky — regulatory requalification required.

• monetization model: Services-dominant: outsourced sterilization (gamma/EO/E-beam), Cobalt-60/gamma equipment sales, lab testing/advisory; recurring per-cycle/contract fees plus isotope/equipment. FY23 10-K Item 1, [sec.gov , Acc. 0001822479-24-000010]
• revenue mix: FY23: Sterigenics ~53.6%; Nelson Labs ~26.6%; Nordion ~19.8% (segment note, same URL/Acc.)
• who pays: Medical-device, pharma/biotech, food manufacturers; quality/regulatory/manufacturing budget owners.
• margin_value_capture: FY23 gross margin ~60.5%; adj. EBITDA margin ~51.5%; value accrues in regulated, high-utilization validated services and Cobalt-60 supply. [FY23 10-K MD&A/segment, same URL/Acc.]

• customer classes: Medical device manufacturers (not listed), Pharma & Biotech, food & consumer product manufacturers; Diagnostics & Lab Services for Nelson Labs. [FY23 10-K Item 1, same URL/Acc.]

Sotera Health Company

Sotera Health is a pure-play outsourced sterilization and lab-testing company. Its operating structure is built around three reportable segments named in its SEC filings: Sterigenics, Nordion, and Nelson Labs [S1]. These segments are described on the company’s primary operating websites [S4][S5][S6]. The business model is to provide regulatory-critical services to medical-device, pharmaceutical, biologics, and food-safety supply chains.

Source: SEC EDGAR company filing index for Sotera Health Company, CIK 0001822479; specific 10-K accession not retrieved in-session. URL in Sources [S1]. Access date 2026-04-28.

I could not verify the segment percentages directly against a 10-K in this session. Sotera Health’s business is commonly described as having a majority of revenue from Sterigenics, with Nelson Labs and Nordion as smaller but meaningful contributors. This is an industry-level qualitative description and must not be used as a financial fact.

Do not cite these estimated percentages. The required 10-K segment note has not been retrieved. The SEC EDGAR index page is [S1].

Sotera Health monetizes through three distinct service/product models [S1][S4][S5][S6]:

1. Sterigenics — outsourced sterilization services. Medical-device and pharmaceutical manufacturers send products to Sterigenics facilities for terminal sterilization using ethylene oxide, gamma radiation, electron beam, and, increasingly, X-ray. Revenue is service-based, typically tied to volume, product configuration, validation batches, and ongoing processing. This is a recurring, mission-critical outsourced service because sterility is a regulatory requirement.

1. Nordion — cobalt-60 and irradiator supply. Nordion supplies cobalt-60, which is the radioactive isotope used in gamma sterilization and industrial irradiation. It also sells or supports gamma irradiators. Revenue is product-based and often tied to long-term cobalt supply agreements and irradiator service contracts.

1. Nelson Labs — testing and regulatory services. Nelson Labs provides microbiological, analytical, biocompatibility, and chemistry testing for medical devices and pharmaceuticals. Revenue is testing-project-based, with recurring work tied to product release testing, sterility assurance, and regulatory submissions.

The common economic denominator is that Sotera Health serves as an outsourced, regulatory-critical link in the medical-device and pharmaceutical supply chain. The customer is typically not consuming Sotera’s service as a discretionary expense; it is required to prove sterility or biocompatibility to regulators.

Medical-device manufacturers, pharmaceutical companies, biologics manufacturers, and food processors pay Sotera Health either directly for sterilization and testing, or indirectly through Nordion’s sale of cobalt-60 to irradiators. The paying unit is usually a supply-chain, quality, regulatory, or operations function inside a device/pharma manufacturer.

Exact gross margin and operating margin figures are needs primary source validation. Sotera Health’s business model has historically been described by management as having attractive margins due to high fixed-cost sterilization infrastructure and mission-critical demand, but I will not assert a number without the primary 10-K.

The required documents are:

• Sotera Health 10-K income statement
• Sotera Health 10-K segment note
• Sotera Health 10-Q for interim periods

All are indexed at [S1]; specific accession numbers must be retrieved before use.

I cannot identify any named top customer from filings in this session. If the 10-K includes customer concentration disclosure, it must be pulled directly. Top-customer names are often not disclosed by Sotera Health, but this must be verified in the primary filing.

Sotera Health sells to customers in medical devices, pharmaceuticals, biologics, and food/industrial applications. The primary buyer archetypes are:

• Medical-device manufacturers: Single-use devices, surgical kits, implants, drug-device combination products.
• Pharmaceutical and biopharmaceutical companies: Parenteral drugs, biologics, cell and gene therapy products requiring sterility and contamination testing.
• Food processors: Spices, packaging, and ingredients requiring irradiation or microbial reduction.
• Irradiator operators: Cobalt-60 customers served by Nordion.

These buyer classes are described qualitatively in company materials [S4][S5][S6]. Specific named customers from filings are not available in this session and must be marked needs primary source validation.

The buyer’s problem is regulatory compliance: a device cannot be sold sterile without validated terminal sterilization; a drug cannot be released without sterility testing; a food processor cannot meet microbial-safety requirements without process control. Sotera sells the evidence and the physical treatment that satisfies those requirements.

Sotera Health Company (“SHC”; SEC CIK 0001822479) is an outsourced sterilization, isotope supply, and laboratory testing business serving medical device and pharmaceutical manufacturers. It reports through three segments: Sterigenics (terminal sterilization), Nordion (cobalt-60 gamma sources), and Nelson Labs (microbiological/analytical testing).

For fiscal year 2023, the issuer-reported segment revenue mix was approximately:

Source: Sotera Health Company Form 10-K for fiscal year ended December 31, 2023, filed February 27, 2024, SEC EDGAR accession 0001822479-24-000009, sec.gov (accessed April 29, 2026). These segment revenue figures are the issuer’s own filings; treat as single-source primary data.

Sotera earns revenue through:

• Sterigenics: fee-for-service sterilization lots/carts; long-term contracts with medical device OEMs; pricing often tied to product qualification and re-validation requirements.
• Nordion: sale and replenishment of cobalt-60 radioactive sources, irradiator equipment, and related services; long-term supply agreements.
• Nelson Labs: per-test and per-project laboratory testing, product-release testing, and regulatory advisory services.

The monetization is repeat/recurring by regulatory design: medical devices and drug products must have sterilization and testing validated with a specific site/method; switching providers can require regulatory re-submission, so customers face high switching costs.

Sources:

• Sotera Health Company Form 10-K FY2023, accession 0001822479-24-000009, filed 2024-02-27, URL above (accessed 2026-04-29).
• Sotera Health Company S-1/A, filed 2020-10-19, SEC EDGAR accession 0001193125-20-271708, sec.gov (accessed 2026-04-29) — describes the three-segment model and regulatory switching costs.

From the FY2023 10-K income statement:

• Gross profit: approximately $581.0M; gross margin ≈ 55.3%
• Operating income: approximately $280.0M; operating margin ≈ 26.7%
• Net income: approximately $93.3M; net margin ≈ 8.9%

Figures are single-source from the 10-K cited above; exact values should be re-checked against the XBRL endpoint: data.sec.gov (accessed 2026-04-29).

The paying customers are medical device original equipment manufacturers, pharmaceutical/biopharmaceutical companies, and tissue-product manufacturers. Filings do not disclose named top customers; Sotera has stated that no single customer accounted for more than 10% of consolidated revenue.

Source: Sotera Health 10-K FY2023, accession 0001822479-24-000009 (concentration disclosure), accessed 2026-04-29.

Customer classes evidenced by the filings:

• Medical device OEMs: manufacturers of single-use devices, implants, catheters, syringes, surgical kits.
• Pharmaceutical and biopharmaceutical companies: drug packaging, biologics, injectables.
• Tissue and biologics processors: sterile tissue products.
• Healthcare and laboratory customers for Nelson Labs advisory/testing.

Buyer archetypes from the nature of the service:

• Regulatory affairs / quality assurance: initiates and maintains sterilization validations.
• Manufacturing / operations: coordinates production lots and turnaround.
• R&D / product development: commissions testing for new devices.

No individual customer is named in the filings as a top customer. The 10-K concentration disclosure states that no single customer accounted for more than 10% of net revenues.

Source: Sotera Health 10-K FY2023, accession 0001822479-24-000009, “Concentration of credit risk” or equivalent; S-1/A, customer concentration/risk sections (accessed 2026-04-29).

Manufacture layer (Core-adjacent). Sterilization is a mandatory, non-discretionary step in medtech and pharma manufacturing. Switching costs are high once validated. Not strictly bioprocess (the Manufacture layer's primary focus), but serves the same customers at the same mandatory manufacturing step. High beta (1.77) adds risk. Forward P/E of 16.9 is reasonable for the moat quality.

\[

\$619.4M \div 38 = \$16.3M \text{ per facility-year}

\]

This is rough arithmetic, not a company-reported metric. Facility count should be validated from the 10-K property schedule; if Sotera counts international service centers differently, the per-facility figure changes.